{"id":367831,"date":"2019-05-15T03:15:04","date_gmt":"2019-05-15T03:15:04","guid":{"rendered":"http:\/\/www.abnewswire.com\/pressreleases\/?p=367831"},"modified":"2019-05-15T03:15:04","modified_gmt":"2019-05-15T03:15:04","slug":"oncology-biosimilars-2019-global-trends-market-size-share-status-swot-analysis-and-forecast-to-2025","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/oncology-biosimilars-2019-global-trends-market-size-share-status-swot-analysis-and-forecast-to-2025_367831.html","title":{"rendered":"Oncology Biosimilars 2019 Global Trends, Market Size, Share, Status, SWOT Analysis and Forecast to 2025"},"content":{"rendered":"
\"\"<\/a><\/p>\n
\n
“Oncology Biosimilars Market”<\/div>\n<\/div>\n<\/div>\n
WiseGuyRerports.com Presents \u201cGlobal Oncology Biosimilars Market Insights, Forecast to 2025\u201d New Document to its Studies Database<\/div>\n

 <\/p>\n

Biosimilar is the identical copy of oncology biologics used for the treatment of cancer and officially approved for the treatment of cancer. These molecules are cost-effective, efficient, and have the same ability as biologics. These molecules are easy to manufacture as compared to biologics and can only be manufactured after patent expiry. Earlier there were various patented biologics available in the market but nowadays most of the patents have expired and few are on the verge of patent expiry. In the past few years, various biosimilars have been approved by FDA for the treatment of various types of cancer such as blood cancer, colorectal cancer, breast cancer, and others. In the near future, it is expected that a few more biosimilars will be introduced in the market thus supporting the growth of the market. 
The global Oncology Biosimilars<\/strong> market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Oncology Biosimilars market based on company, product type, end user and key regions.<\/p>\n

 <\/strong><\/p>\n

 Request Free Sample Report<\/strong> @ https:\/\/www.wiseguyreports.com\/sample-request\/3981664-global-oncology-biosimilars-market-insights-forecast-to-2025<\/a>                         <\/p>\n

                                    <\/p>\n

The following manufacturers are covered in this report, with sales, revenue, market share<\/strong> for each company: 
Celltrion 
Biocon 
Dr. Reddy’s Laboratories 
STADA Arzneimittel AG 
Intas Pharmaceuticals 
Pfizer 
Sandoz International 
Teva Pharmaceutical Industries Ltd 
Apotex 
BIOCAD<\/strong><\/p>\n

Market size by Product 
<\/strong>mAb 
Immunomodulators 
Hematopoietic Agents 
G-CSF  
Others 
Market size by End User 
Retail Pharmacies 
Hospital Pharmacy 
Online Pharmacy<\/p>\n

Market size by Region 
<\/strong>North America 
United States 
Canada 
Mexico 
Asia-Pacific 
China 
India 
Japan <\/p>\n

The study objectives of this report are: 
<\/strong>To study and analyze the global Oncology Biosimilars market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025. 
To understand the structure of Oncology Biosimilars market by identifying its various subsegments. 
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks). 
Focuses on the key global Oncology Biosimilars companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development. 
To project the value and sales volume of Oncology Biosimilars submarkets, with respect to key regions. 
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.<\/p>\n

 <\/strong><\/p>\n

Complete Report Details @<\/strong> https:\/\/www.wiseguyreports.com\/reports\/3981664-global-oncology-biosimilars-market-insights-forecast-to-2025<\/a>                   <\/p>\n

 <\/p>\n

Table Of Contents:      <\/strong><\/p>\n

1 Study Coverage <\/strong><\/p>\n

2 Executive Summary <\/p>\n

<\/strong><\/p>\n

3 Breakdown Data by Manufacturers <\/p>\n

<\/strong><\/p>\n

4 Breakdown Data by Product <\/p>\n

<\/strong><\/p>\n

5 Breakdown Data by End User <\/p>\n

<\/strong><\/p>\n

6 North America <\/p>\n

<\/strong><\/p>\n

7 Europe <\/p>\n

<\/strong><\/p>\n

8 Asia Pacific <\/p>\n

<\/strong><\/p>\n

9 Central & South America <\/p>\n

<\/strong><\/p>\n

10 Middle East and Africa <\/p>\n

<\/strong><\/p>\n

11 Company Profiles <\/p>\n

<\/strong><\/p>\n

12 Future Forecast <\/p>\n

<\/strong><\/p>\n

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis <\/p>\n

<\/strong><\/p>\n

14 Value Chain and Sales Channels Analysis <\/p>\n

<\/strong><\/p>\n

15 Research Findings and Conclusion<\/strong><\/p>\n

16 Appendix <\/strong><\/p>\n


List of Tables and Figures<\/strong><\/p>\n

 <\/p>\n

Continued…….<\/strong>                                                     <\/p>\n

Also Read : Global HGH Biosimilars Market Research Report 2019<\/a><\/strong><\/p>\n

Media Contact<\/span>
Company Name:<\/strong> Wiseguyreports.com<\/a>
Contact Person:<\/strong> Norah Trent
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> +1 646 845 9349, +44 208 133 9349
City:<\/strong> Pune
State:<\/strong> Maharashtra
Country:<\/strong> India
Website:<\/strong> www.wiseguyreports.com<\/a><\/p>\n

 <\/p>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

“Oncology Biosimilars Market” WiseGuyRerports.com Presents \u201cGlobal Oncology Biosimilars Market Insights, Forecast to 2025\u201d New Document to its Studies Database   Biosimilar is the identical copy of oncology biologics used for the treatment of cancer and officially approved for the treatment … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401],"tags":[],"class_list":["post-367831","post","type-post","status-publish","format-standard","hentry","category-Business"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/367831","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=367831"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/367831\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=367831"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=367831"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=367831"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}